GSK plc (GSK) Stock Rises as FDA Approves Nucala for COPD, CHMP Backs Blenrep for Cancer Treatment

By Yahoo! Finance | 1 month ago

GSK plc's market outlook is strengthened by FDA approvals for Nucala in COPD and CHMP's positive recommendation for Blenrep in multiple myeloma. These milestones are expected to boost the Specialty Medicines segment and drive 4.6% annual revenue growth.

Did you find this insightful?